Nitrome Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Nitrome Biosciences's estimated annual revenue is currently $6.7M per year.
- Nitrome Biosciences's estimated revenue per employee is $155,000
Employee Data
- Nitrome Biosciences has 43 Employees.
- Nitrome Biosciences grew their employee count by 8% last year.
Nitrome Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO/CSO | Reveal Email/Phone |
Nitrome Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Nitrome Biosciences?
Nitrome Biosciences has discovered and identified a new class of enzymes. As a platform company developing drugs against a newly identified class of enzymes, we will have found and characterized this class of enzymes and will have paved a novel inroad into the proprietary development of disease-modifying therapies. We are initially targeting Parkinson's disease and developing cures for multiple aging-dependent diseases, including other neurodegenerative diseases, Type II diabetes, heart disease and cancer.
keywords:N/A
N/A
Total Funding
43
Number of Employees
$6.7M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nitrome Biosciences News
2022-03-30 - Nitrase Therapeutics Receives New Grant from The Michael J ...
Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6M | 43 | 39% | N/A |
#2 | $5.1M | 44 | -12% | N/A |
#3 | $5.1M | 44 | N/A | N/A |
#4 | $7.9M | 45 | 29% | N/A |
#5 | $5.2M | 45 | 29% | N/A |